Market Insights Health Hospitals Inpatient Care

Neoplasm Treatment - Sri Lanka

Sri Lanka

In Sri Lanka, the revenue in the Neoplasm Treatment market is expected to reach US$111.90m in 2024.
Looking ahead, the market is projected to experience a steady annual growth rate (CAGR 2024-2029) of -5.45%, which will lead to a market volume of US$84.55m by 2029.
It is worth noting that in a global comparison, United States will generate the highest revenue in this market, with an estimated amount of US$90.56bn in 2024.
Sri Lanka's neoplasm treatment market is witnessing a surge in demand for advanced immunotherapy techniques.

Key regions: Europe, Canada, Brazil, United States, United Kingdom

Market

Region

Region comparison

Currency

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on revenue received by hospitals from public or private sources, allocated to the country where the money is spent, including VAT if applicable.

Modeling approach / Market size:

Market sizes are determined by a bottom-up approach, based on a specific rationale for each market market. Next, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, public health spend, and GDP. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.